BUZZ-GenScript jumps on associate's cancer drug's $334 mln sales

Reuters

23 Jan

** GenScript Biotech jumps as much as 7.2% to HK$10.98, highest since Dec. 11, 2024

** Stock set for biggest one-day pct rise since Oct. 22, 2024 and is on course for sixth consecutive session of gains

** Co's associate Legend Biotech announces its drug CARVYKTI, used to treat cancer of the bone marrow, brought in ~$334 mln in net trade sales in quarter ended Dec. 31, 2024, up from year-ago $159 mln

** GenScript fell 50.5% last year

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2505028031"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505028031\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2505028031?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-23 11:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505028031","market":"hk","top_or_hot":-1,"title":"BUZZ-GenScript jumps on associate's cancer drug's $334 mln sales","media":"Reuters","content":"<html><body><p>** GenScript Biotech    jumps as much as 7.2% to HK$10.98, highest since Dec. 11, 2024</p><p>   ** Stock set for biggest one-day pct rise since Oct. 22, 2024 and is on course for sixth consecutive session of gains</p><p>   ** Co's associate Legend Biotech    announces its drug CARVYKTI, used to treat cancer of the bone marrow, brought in ~$334 mln in net trade sales in quarter ended Dec. 31, 2024, up from year-ago $159 mln</p><p>   ** GenScript fell 50.5% last year</p><p> (Reporting by Donny Kwok)</p><p>((donny.kwok@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>BUZZ-GenScript jumps on associate's cancer drug's $334 mln sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-GenScript jumps on associate's cancer drug's $334 mln sales\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-23 11:51</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>** GenScript Biotech    jumps as much as 7.2% to HK$10.98, highest since Dec. 11, 2024</p><p>   ** Stock set for biggest one-day pct rise since Oct. 22, 2024 and is on course for sixth consecutive session of gains</p><p>   ** Co's associate Legend Biotech    announces its drug CARVYKTI, used to treat cancer of the bone marrow, brought in ~$334 mln in net trade sales in quarter ended Dec. 31, 2024, up from year-ago $159 mln</p><p>   ** GenScript fell 50.5% last year</p><p> (Reporting by Donny Kwok)</p><p>((donny.kwok@thomsonreuters.com))</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2505028031","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505028031","pubTimestamp":1737604304,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** GenScript Biotech    jumps as much as 7.2% to HK$10.98, highest since Dec. 11, 2024   ** Stock set for biggest one-day pct rise since Oct. 22, 2024 and is on course for sixth consecutive session of gains   ** Co's associate Legend Biotech    announces its drug CARVYKTI, used to treat cancer of the bone marrow, brought in ~$334 mln in net trade sales in quarter ended Dec. 31, 2024, up from year-ago $159 mln   ** GenScript fell 50.5% last year ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"BUZZ-GenScript因associate抗癌药物销售额达3.34亿美元而跃升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":0.9},"content_text":"** GenScript Biotech    jumps as much as 7.2% to HK$10.98, highest since Dec. 11, 2024   ** Stock set for biggest one-day pct rise since Oct. 22, 2024 and is on course for sixth consecutive session of gains   ** Co's associate Legend Biotech    announces its drug CARVYKTI, used to treat cancer of the bone marrow, brought in ~$334 mln in net trade sales in quarter ended Dec. 31, 2024, up from year-ago $159 mln   ** GenScript fell 50.5% last year (Reporting by Donny Kwok)((donny.kwok@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}